How easy is it to Diagnosed with a Mental Illness? Well in the UK it is Very

According to a survey last year, one in four adults has been diagnosed with a mental illness at some stage during their lifetime, the annual health survey for England suggests.
This survey asked 5000 adults and 26% indicated they had been diagnosed with a mental illness. Almost 20% said they were diagnosed with depression with women getting the highest diagnosis.
Around the time of this survey
David Cameron the prime minister at the time made a speech to promise action on "treatable problems", including mental illnesses and addiction. He had pledged 1 Billion pounds to the cause.

What the Prime Minister and government officials don’t seem to get is that psychiatry is the problem and not the solution. Psychiatry and mental health professionals diagnose mental illness with just a few questions and a patient is on a drug right after the interview. To psychiatry mental health is a revenue stream. They are not into the profession to cure. They have no solutions, and never will. Keep in mind psychiatry used ice picks to ‘cure’ the mentally ill in the 40’s and 50’s. They used strait jacket and electric shock today. They only remedy is a pill today. It has been proven time and time again that a placebo works better than their pills. Virtually all campus, and mass shootings involve a mentally ill patient on one of their drugs.

The UK just gave 1 billion pounds to accelerate the mess that is mental illness. It will get worse and worse as psychiatry is clueless about mental illness. They know how to pry money out of a naive government though.

Another Day at the Pharma: Pfizer fined 107 Million in Overbilling

This is a report via Reuters

Britain’s competition watchdog has fined Pfizer a record 84.2 million pounds (US$107 million) for its role in ramping up the cost of an epilepsy drug by as much as 2,600 percent.
In the case of phenytoin sodium capsules, the UK price charged for 100 mg packs of the drug jumped from 2.83 pounds to 67.50 in 2012, before reducing to 54.00 from May 2014.
As a result, annual spending on the capsules by Britain’s National Health Service rose from 2 million pounds in 2012 to about 50 million in 2013. The CMA said UK prices were many times higher than elsewhere in Europe.
Pfizer used to market the medicine under the brand name Epanutin but sold the rights to Flynn, a privately owned British company, in September 2012.
It was then debranded, meaning that it was no longer subject to price regulation, and the price soared.
“The companies deliberately exploited the opportunity offered by debranding to hike up the price for a drug which is relied upon by many thousands of patients,” Philip Marsden, chairman of the CMA’s case decision group, said on Wednesday.
“This is the highest fine the CMA has imposed and it sends out a clear message to the sector that we are determined to crack down on such behavior.”
Pfizer said in a statement it planned to appeal all aspects of the CMA’s verdict.
The U.S. drug maker said the medicine had been loss-making and it was therefore forced to consider whether it could continue supplying it. Pfizer added that the price set by Flynn was actually 25 to 40 percent less than the cost of an equivalent tablet form from another supplier.
Flynn also plans to appeal. Chief executive David Fakes said punishing Flynn for selling phenytoin capsules for less than phenytoin tablets “beggars’ belief”.